ReviewDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Gastrodin as a nephroprotective agent: Molecular docking-based modulation of oxidative stress, fibrosis, and inflammation.
Review in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney diseases are a heterogeneous group of disorders characterised by progressive structural and functional impairment of the kidneys, and homeostatic imbalance. Among these, acute kidney disease (AKD), and chronic kidney disease (CKD) are the most prevalent and clinically significant forms. Notably, the high mobility group box 1/receptor for advanced glycation end products (HMGB1/RAGE) axis activates nuclear factor kappa B (NF-κB), a pivotal transcription factor responsible for pro-inflammatory cytokine production. Additionally, transforming growth factor-β1 (TGF-β1) signaling through Sma and Mad-related protein (SMADs) and mitogen-activated protein kinases (MAPK) pathways induces extracellular matrix (ECM) accumulation, contributing to tissue fibrosis.
objectiveTo review the renoprotective potential of gastrodin and elucidate its molecular interactions involved in kidney diseases.
methodsGastrodin, a bioactive phenolic glycoside derived from Gastrodia elata, was evaluated using reported pharmacological evidence and molecular docking analyses. Key signaling pathways and molecular targets involved in renal injury, including RAGE, NF-κB, TGF-β1, HMGB1, NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, and the SIRT1/Nrf2 axis, were assessed to determine the multitargeted therapeutic potential of gastrodin.
resultsSeveral studies have demonstrated that gastrodin exerts its renoprotective effects by modulating key molecular mediators, including RAGE, NF-κB, TGF-β1, HMGB1, NLRP3 inflammasome, and the SIRT1/Nrf2 signaling axis, thereby providing a multitargeted protective mechanism against renal inflammation, oxidative stress, and fibrosis. Molecular docking analyses further demonstrate strong binding affinities of gastrodin with SIRT1 (-8.0 kcal/mol), RAGE (-7.5 kcal/mol), TGF-β1 receptor (-6.1 kcal/mol), and HMGB1 (-6.0 kcal/mol).
conclusionCollectively, these findings highlight gastrodin as a promising renoprotective agent, and mechanistic insights into its molecular interactions may inform future preclinical investigations and translational strategies in renal pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.